Although identifying cancer-subtype biomarker is challenging, UALCAN analysis suggested that the methylation of the PRKY promoter is absent in many other cancers (lung, liver, colorectal, esophageal, bladder, and pancreatic cancers). Here, PRKY is linked to pancreatic neoplasm.